Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 35%
Hold 29%
Sell 0%
Strong Sell 6%

Bulls say

Arvinas Inc. has demonstrated a significant increase in the projected enterprise value, rising from $627 million to $959 million, which reflects the growing confidence in its therapeutic pipeline and strategic partnerships, including the collaboration with Novartis on luxdegalutamide (ARV-766). The enhanced valuations of key product candidates such as ARV-102 and ARV-806 further underscore the company’s solid position in the biotechnology sector, with respective valuations increasing to $247 million and $63 million. The overall positive adjustments in valuations are indicative of Arvinas's potential for continued financial growth and market impact, particularly as these products progress through their clinical development stages.

Bears say

Arvinas Inc. faces a negative outlook primarily due to reduced projections regarding potential revenue generation and market penetration for its therapies, notably with the peak revenue estimate for vepdegestrant being downgraded significantly from $641.2 million to $296.9 million by 2035. Additionally, the company exhibits challenges in maintaining its competitive positioning in the oncology field, particularly as its ORR in pancreatic ductal adenocarcinoma (PDAC) patients is anticipated to decline compared to other therapeutic options, indicating possible market share loss and diminished growth prospects. Furthermore, concerns regarding access to capital may impede the company's critical operations and delay paths to profitability, which further exacerbates the overall financial uncertainty surrounding its stock performance.

Arvinas Inc (ARVN) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 35% recommend Buy, 29% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 17 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.